We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

2 hedge funds and large institutions have $228K invested in CNS Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

35% less capital invested

Capital invested by funds: $351K → $228K (-$123K)

83% less funds holding

Funds holding: 12 → 2 (-10)

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

Holders
2
Holders Change
-10
Holders Change %
-83.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$1.26M
2
UBS Group
UBS Group
Switzerland
+$21.3K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$171K
2
VF
Virtu Financial
New York
-$34K
3
Citadel Advisors
Citadel Advisors
Florida
-$33K
4
SAF
Smith Anglin Financial
Texas
-$32.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$21.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$223K +$1.26M +236 New
UBS Group
2
UBS Group
Switzerland
$4.15K +$21.3K +4 New
TRCT
3
Tower Research Capital (TRC)
New York
$182 – – –
Wells Fargo
4
Wells Fargo
California
$6 – – –
GRP
5
Global Retirement Partners
California
$3 – – –
Morgan Stanley
6
Morgan Stanley
New York
$3 – – –
Bank of America
7
Bank of America
North Carolina
$2 – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$2 – – –
PA
9
Parallel Advisors
California
$2 – – –
PMFA
10
Plante Moran Financial Advisors
Michigan
$2 – – –
AC
11
Armistice Capital
New York
– -$171K -16 Closed
Citadel Advisors
12
Citadel Advisors
Florida
– -$33K -3 Closed
SAF
13
Smith Anglin Financial
Texas
– -$32.7K -3 Closed
VF
14
Virtu Financial
New York
– -$34K -3 Closed
Vanguard Group
15
Vanguard Group
Pennsylvania
– -$21.1K -2 Closed
FWA
16
FSM Wealth Advisors
Ohio
– -$6.91K -1 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$10.2K -1 Closed
HF
18
HRT Financial
New York
– -$7K -1 Closed
Jane Street
19
Jane Street
New York
– -$9.91K -1 Closed
State Street
20
State Street
Massachusetts
– -$8.16K -1 Closed
TSS
21
Two Sigma Securities
New York
– -$7.89K -1 Closed
XT
22
XTX Topco
Cayman Islands
– -$6.78K -1 Closed

CNSP Hedge Fund Activity: Q2 2024 in Review

2 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2024, worth a combined $228K — down 35% from $351K a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CNSP and 2 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.26M. The largest seller was Armistice Capital, exiting entirely with an estimated $171K sold.

  • 2 institutional investors held CNS Pharmaceuticals (CNSP) as of Q2 2024, down from 12 in Q1 2024.
  • Funds reported $228K of CNS Pharmaceuticals stock for Q2 2024, down 35% quarter-over-quarter.
  • 2 funds opened new CNS Pharmaceuticals positions in Q2 2024 and 12 closed out, a net change of -10 holders.
  • The largest CNS Pharmaceuticals buyer in Q2 2024 was Anson Funds Management, an estimated $1.26M added.
  • The largest CNS Pharmaceuticals seller in Q2 2024 was Armistice Capital, an estimated $171K sold.

Based on aggregated 13F filings for Q2 2024.